全文获取类型
收费全文 | 119篇 |
免费 | 17篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 4篇 |
妇产科学 | 2篇 |
基础医学 | 17篇 |
口腔科学 | 4篇 |
临床医学 | 9篇 |
内科学 | 27篇 |
皮肤病学 | 3篇 |
神经病学 | 15篇 |
特种医学 | 2篇 |
外科学 | 16篇 |
预防医学 | 12篇 |
眼科学 | 3篇 |
药学 | 12篇 |
中国医学 | 1篇 |
肿瘤学 | 6篇 |
出版年
2023年 | 4篇 |
2022年 | 1篇 |
2021年 | 17篇 |
2020年 | 12篇 |
2019年 | 12篇 |
2018年 | 11篇 |
2017年 | 9篇 |
2016年 | 5篇 |
2015年 | 9篇 |
2014年 | 11篇 |
2013年 | 8篇 |
2012年 | 6篇 |
2011年 | 9篇 |
2010年 | 5篇 |
2009年 | 3篇 |
2008年 | 2篇 |
2007年 | 2篇 |
2006年 | 3篇 |
2004年 | 2篇 |
2003年 | 1篇 |
2002年 | 1篇 |
1998年 | 2篇 |
1997年 | 1篇 |
排序方式: 共有136条查询结果,搜索用时 93 毫秒
1.
Patricia Estefania Ayala Aguirre Anna Paola Strieder Matheus Lotto Thaís Marchini Oliveira Daniela Rios Agnes Ftima Pereira Cruvinel Thiago Cruvinel 《International journal of paediatric dentistry / the British Paedodontic Society [and] the International Association of Dentistry for Children》2020,30(1):27-34
2.
Schwartzman Jessica M. Millan Maria Estefania Uljarevic Mirko Gengoux Grace W. 《Journal of autism and developmental disorders》2022,52(2):738-757
Journal of Autism and Developmental Disorders - Parents of children with autism spectrum disorder (ASD) experience elevated stress, yet parent-specific interventions are sparse. Thirty-five parents... 相似文献
3.
Gen Hamanaka Tomoya Kubo Ryo Ohtomo Hajime Takase Estefania Reyes-Bricio Shuntaro Oribe Noriko Osumi Josephine Lok Eng H. Lo Ken Arai 《Glia》2020,68(7):1435-1444
Upon infection or brain damage, microglia are activated to play roles in immune responses, including phagocytosis and soluble factor release. However, little is known whether the event of phagocytosis could be a trigger for releasing soluble factors from microglia. In this study, we tested if microglia secrete a neurovascular mediator matrix metalloproteinase-9 (MMP-9) after phagocytosis in vitro. Primary microglial cultures were prepared from neonatal rat brains. Cultured microglia phagocytosed Escherichia coli bioparticles within 2 hr after incubation and started to secrete MMP-9 at around 12 hr after the phagocytosis. A TLR4 inhibitor TAK242 suppressed the E. coli-bioparticle-induced MMP-9 secretion. However, TAK242 did not change the engulfment of E. coli bioparticles in microglial cultures. Because lipopolysaccharides (LPS), the major component of the outer membrane of E. coli, also induced MMP-9 secretion in a dose–response manner and because the response was inhibited by TAK242 treatment, we assumed that the LPS-TLR4 pathway, which was activated by adhering to the substance, but not through the engulfing process of phagocytosis, would play a role in releasing MMP-9 from microglia after E. coli bioparticle treatment. To support the finding that the engulfing step would not be a critical trigger for MMP-9 secretion after the event of phagocytosis in microglia, we confirmed that cell debris and amyloid beta were both captured into microglia via phagocytosis, but neither of them induced MMP-9 secretion from microglia. Taken together, these data demonstrate that microglial response in MMP-9 secretion after phagocytosis differs depending on the types of particles/substances that microglia encountered. 相似文献
4.
5.
Aitor Hernandez-Hernandez Alfredo Gea Miguel Ruiz-Canela Estefania Toledo Juan-José Beunza Maira Bes-Rastrollo Miguel A. Martinez-Gonzalez 《Nutrients》2015,7(11):9116-9126
Background: We assessed the still unclear effect of the overall alcohol-drinking pattern, beyond the amount of alcohol consumed, on the incidence of cardiovascular clinical disease (CVD). Methods: We followed 14,651 participants during up to 14 years. We built a score assessing simultaneously seven dimensions of alcohol consumption to capture the conformity to a traditional Mediterranean alcohol-drinking pattern (MADP). It positively scored moderate alcohol intake, alcohol intake spread out over the week, low spirit consumption, preference for wine, red wine consumption, wine consumed during meals and avoidance of binge drinking. Results: During 142,177 person-years of follow-up, 127 incident cases of CVD (myocardial infarction, stroke or cardiovascular mortality) were identified. Compared with the category of better conformity with the MADP, the low-adherence group exhibited a non-significantly higher risk (HR) of total CVD ((95% CI) = 1.55 (0.58–4.16)). This direct association with a departure from the traditional MADP was even stronger for cardiovascular mortality (HR (95% CI) = 3.35 (0.77–14.5)). Nevertheless, all these associations were statistically non-significant. Conclusion: Better conformity with the MADP seemed to be associated with lower cardiovascular risk in most point estimates; however, no significant results were found and more powered studies are needed to clarify the role of the MADP on CVD. 相似文献
6.
7.
8.
9.
Potera Joanna Kambhatla Soumyasri Gauto-Mariotti Estefania Manadan Augustine 《Clinical rheumatology》2021,40(12):4845-4851
Clinical Rheumatology - Rheumatoid arthritis (RA) patients have high infection rates. Streptococcus pneumoniae, herpes zoster (HZV), and influenza are common and potentially preventable causes of... 相似文献
10.
Monica Cabrero Alejandro Martin Javier Briones Jorge Gayoso Isidro Jarque Javier López Carlos Grande Inmaculada Heras Reyes Arranz Teresa Bernal Estefania Perez-Lopez Oriana López-Godino Eulogio Conde Dolores Caballero 《Biology of blood and marrow transplantation》2017,23(1):53-59
We designed a phase II clinical trial including Y-90 ibritumomab-tiuxetan as part of a reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (Clinical Trials Identifier: NCT00644371). Eligible patients had high-risk relapsed/refractory aggressive lymphoma. The conditioning regimen consisted of rituximab 250?mg (days ?21 and ?14), Y-90 ibritumomab IV (.4?m Ci/kg, day ?14), fludarabine 30?mg/m2 i.v. (days ?3 and ?2) plus melphalan 70?mg/m2 i.v. (days ?3 and ?2) or 1 dose of melphalan and thiotepa 5?mg/kg (day ?8). Donors were related. Eighteen patients were evaluable. At the time of transplantation, responses were complete remission (CR) (n = 7, 39%), partial remission (n = 6, 33%) or refractory disease (n = 4, 28%). Y-90-ibritumomab infusions were well tolerated, with no adverse reactions. Nonrelapse mortality at 1 year was 28%. Median follow-up was 46 (range, 39 to 55) months. Estimated 1-year progression-free survival (PFS) was 50%, and 4-year overall survival (OS) and PFS were both 44.4%. CR at the moment of AlloSCT had significant impact on PFS (71% versus 27%, P?=?.046) and OS (71% versus 27%, P?=?.047). Our results show that Y-90-ibritumomab-tiuxetan as a component of RIC for AlloSCT is feasible in patients with high-risk B cell lymphoma. Development of phase III clinical trials is needed to clarify the contribution of radioimmunotherapy to RIC AlloSCT. 相似文献